Regulatory ready Capitalize on Royal Emerald's DEA-registered Schedule I bulk manufacturing capability and FDA cGMP, EU GMP, ISO-aligned quality systems to position as a reliable supplier of compliant botanical drug substances for clinical research, investigational drugs, and international export opportunities.

Specialized portfolio Target opportunities around medical cannabis and other novel Schedule I botanical substances used in research programs, translational science, and government or academic testing, emphasizing fast onboarding and compliant distribution.

Financing credibility Leverage the recent $17M debt financing to discuss scalable supply, capacity expansion, and longer-term distribution agreements with research institutions and contract research organizations seeking dependable botanical drug substance sourcing.

Global research access Highlight capabilities to serve international medical export markets and academic/government partnerships, offering end-to-end compliance, traceability, and cross-border support for investigational and clinical studies.

Strategic partnerships Explore alliances with large-scale pharma players, CROs, and biotech firms seeking compliant botanical ingredients, with a focus on accelerated regulatory milestones, quality assurance, and secure supply chains.